Prime Medicine Launches With $315m To Fund New Approach To Gene Editing
The company sees its gene-editing technology, which it compares to a DNA “word processor,” as having potentially broad applicability.
The company sees its gene-editing technology, which it compares to a DNA “word processor,” as having potentially broad applicability.